Herantis Pharma - Halting Neurodegenerative Diseases

Stocks
,
1086

Inside information: Herantis Pharma selected to receive EUR 8.0 million in funding from the Horizon Europe 2025 program for the HER-096 Phase 2 clinical trial | Kauppalehti

Very good news! 8 million is a lot of money and shows how much faith there is in HER-096.

25 Likes